I am somewhat new here. Do you think the ASCO abstracts will tell us anything fresh and new that would cause the stock to have a super nice spike? or will it just reiterate rehash the stuff we already know?
J. C. Byrd is the best in the business. He will correlate the drug with individual cases and trials. He will show how this drug is far more better than CAL 101, TRU016, PHA767491, ABT733, ABT265, GA101, STI571 etc.
He will also discuss its uses with other more available drug to stem the growth of cancer. Wait. Thats why patience is a virtue. The Hedge fund, and brokerage houses are finally waking up. No news is actually great news.